Dennis J. Slamon
机构：University of California, Los Angeles, UCLA Health, Cancer Research Center · ORCID：0000-0002-6330-498X
发表论文 992 篇 · 总被引 101934 次 · h-index 126
代表论文
- Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival (2025 · ESMO Open · 被引 36)
- Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer (2025 · JAMA Oncology · 被引 21)
- Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence (2025 · Journal of Clinical Oncology · 被引 1)
- Editor’s Note: Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo (2026 · Clinical Cancer Research)
- Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies (2026 · Clinical Cancer Research)
- Prognostic and predictive impact of baseline gene expression (exp) in the NATALEE trial of adjuvant (adj) ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in HR+/HER2− early breast cancer (EBC). (2026 · Journal of Clinical Oncology)